PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1463778
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1463778
Drug Discovery Services Market Size and Share Analysis by Process, Type, Drug Type, Therapeutic Area, End User - Global Industry Demand Forecast to 2030
Market Overview
In 2023, the estimated value of the global drug discovery services market is USD 21.0 billion, projected to reach USD 54.2 billion by 2030. This growth represents a Compound Annual Growth Rate of 14.7% during the period from 2024 to 2030.
The growing research and development investments of the biopharmaceutical and pharmaceutical industries, the increasing need for outsourcing analytical testing facilities, steps for orphan drug and rare illness research, and the costly nature of the in-house drug expansion procedure are all opening up new revenue gates in the worldwide industry.
One of the reasons for the escalating demand for outsourcing clinical testing and analytical research services for biopharmaceutical drugs is the rising expenditure of R&D activities that are majorly channelled toward orphan drugs that are meant to suppress rare conditions.
On the other hand, the biopharmaceutical industry has been growing exceptionally due to the ever-increasing demands for biologics and the invention of and manufacturing of several innovative and life-saving drugs. Moreover, the bioscience industry profits from the investment in research of the new covered drugs for common and rare diseases. The market of drug discovery is also solving the problem of patents' expiration as well as the growing need for biologics in emerging economies.
Key Insights
In 2023, the hit-to-lead identification category held the largest share of 35% in the drug discovery services industry.
This procedure is vital in initial drug research and includes outsourcing to attain economies of scale and effectiveness for medicinal businesses.
Pioneering in-silico methods such as computer-aided drug discovery and structure-based medication designs contribute to the development of this category.
High-throughput screening plays a major role in hit-to-lead identification, eased by improvements in robotics, liquid management, plate reader discovery, and computing power.
Because of the dedicated and expensive nature of HTS, several organizations, particularly those with limited backing, select to outsource such services to Contract Research Organizations for high-quality and lucrative solutions.
In 2023, the chemistry category grips a leading share of 60% in the market.
Besides drug discovery, medicinal chemistry provides action at every stage, starting from pre-clinical evaluation to the delivery of a drug candidate.
The medical chemistry market is growing as companies work to find new ways to outsource tasks such as R&D services.
Such growth is continuously fostered by an increase in the number of overhead costs incurred during the pharmaceutical discovery and development processes.
Small-molecule drugs category grips a substantial industry share and is vital in emerging novel treatments worldwide.
Small-molecule drugs account for 50% of specialty drug sales and comprised over 75% of all FDA approvals in 2020.
They play a critical role in treating cancer, autoimmune diseases, cardiovascular disorders, and respiratory conditions.
The North American region holds the largest industry share of 55% in the recent years in drug advancement services.
The region aids from several Contract Research Organizations and Contract Manufacturing Organizations backing key pharmaceutical and biopharmaceutical firms, contributing to industry growth.
Numerous newly developed drugs have their patents held in the U.S., additionally boosting the industry.
Reasons propelling industry development include an increasing elderly populace, growing occurrence of chronic illnesses, technical improvements in biotechnology and pharmaceutical industries, recognized reimbursement guidelines, advanced medicinal infrastructure, rising awareness of initial disease diagnosis, and the reequipment for better patient care.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by process
- 1.4.2. Market size breakdown, by type
- 1.4.3. Market size breakdown, by drug type
- 1.4.4. Market size breakdown, by therapeutic area
- 1.4.5. Market size breakdown, by end user
- 1.4.6. Market size breakdown, by region
- 1.4.7. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Process (2017-2030)
- 6.3. Market Revenue, by Type (2017-2030)
- 6.4. Market Revenue, by Drug Type (2017-2030)
- 6.5. Market Revenue, by Therapeutic Area (2017-2030)
- 6.6. Market Revenue, by End User (2017-2030)
- 6.7. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Process (2017-2030)
- 7.3. Market Revenue, by Type (2017-2030)
- 7.4. Market Revenue, by Drug Type (2017-2030)
- 7.5. Market Revenue, by Therapeutic Area (2017-2030)
- 7.6. Market Revenue, by End User (2017-2030)
- 7.7. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Process (2017-2030)
- 8.3. Market Revenue, by Type (2017-2030)
- 8.4. Market Revenue, by Drug Type (2017-2030)
- 8.5. Market Revenue, by Therapeutic Area (2017-2030)
- 8.6. Market Revenue, by End User (2017-2030)
- 8.7. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Process (2017-2030)
- 9.3. Market Revenue, by Type (2017-2030)
- 9.4. Market Revenue, by Drug Type (2017-2030)
- 9.5. Market Revenue, by Therapeutic Area (2017-2030)
- 9.6. Market Revenue, by End User (2017-2030)
- 9.7. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Process (2017-2030)
- 10.3. Market Revenue, by Type (2017-2030)
- 10.4. Market Revenue, by Drug Type (2017-2030)
- 10.5. Market Revenue, by Therapeutic Area (2017-2030)
- 10.6. Market Revenue, by End User (2017-2030)
- 10.7. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Process (2017-2030)
- 11.3. Market Revenue, by Type (2017-2030)
- 11.4. Market Revenue, by Drug Type (2017-2030)
- 11.5. Market Revenue, by Therapeutic Area (2017-2030)
- 11.6. Market Revenue, by End User (2017-2030)
- 11.7. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Process (2017-2030)
- 12.3. Market Revenue, by Type (2017-2030)
- 12.4. Market Revenue, by Drug Type (2017-2030)
- 12.5. Market Revenue, by Therapeutic Area (2017-2030)
- 12.6. Market Revenue, by End User (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Process (2017-2030)
- 13.3. Market Revenue, by Type (2017-2030)
- 13.4. Market Revenue, by Drug Type (2017-2030)
- 13.5. Market Revenue, by Therapeutic Area (2017-2030)
- 13.6. Market Revenue, by End User (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Process (2017-2030)
- 14.3. Market Revenue, by Type (2017-2030)
- 14.4. Market Revenue, by Drug Type (2017-2030)
- 14.5. Market Revenue, by Therapeutic Area (2017-2030)
- 14.6. Market Revenue, by End User (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Process (2017-2030)
- 15.3. Market Revenue, by Type (2017-2030)
- 15.4. Market Revenue, by Drug Type (2017-2030)
- 15.5. Market Revenue, by Therapeutic Area (2017-2030)
- 15.6. Market Revenue, by End User (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Process (2017-2030)
- 16.3. Market Revenue, by Type (2017-2030)
- 16.4. Market Revenue, by Drug Type (2017-2030)
- 16.5. Market Revenue, by Therapeutic Area (2017-2030)
- 16.6. Market Revenue, by End User (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Process (2017-2030)
- 17.3. Market Revenue, by Type (2017-2030)
- 17.4. Market Revenue, by Drug Type (2017-2030)
- 17.5. Market Revenue, by Therapeutic Area (2017-2030)
- 17.6. Market Revenue, by End User (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Process (2017-2030)
- 18.3. Market Revenue, by Type (2017-2030)
- 18.4. Market Revenue, by Drug Type (2017-2030)
- 18.5. Market Revenue, by Therapeutic Area (2017-2030)
- 18.6. Market Revenue, by End User (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Process (2017-2030)
- 19.3. Market Revenue, by Type (2017-2030)
- 19.4. Market Revenue, by Drug Type (2017-2030)
- 19.5. Market Revenue, by Therapeutic Area (2017-2030)
- 19.6. Market Revenue, by End User (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Process (2017-2030)
- 20.3. Market Revenue, by Type (2017-2030)
- 20.4. Market Revenue, by Drug Type (2017-2030)
- 20.5. Market Revenue, by Therapeutic Area (2017-2030)
- 20.6. Market Revenue, by End User (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Process (2017-2030)
- 21.3. Market Revenue, by Type (2017-2030)
- 21.4. Market Revenue, by Drug Type (2017-2030)
- 21.5. Market Revenue, by Therapeutic Area (2017-2030)
- 21.6. Market Revenue, by End User (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Process (2017-2030)
- 22.3. Market Revenue, by Type (2017-2030)
- 22.4. Market Revenue, by Drug Type (2017-2030)
- 22.5. Market Revenue, by Therapeutic Area (2017-2030)
- 22.6. Market Revenue, by End User (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Process (2017-2030)
- 23.3. Market Revenue, by Type (2017-2030)
- 23.4. Market Revenue, by Drug Type (2017-2030)
- 23.5. Market Revenue, by Therapeutic Area (2017-2030)
- 23.6. Market Revenue, by End User (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Process (2017-2030)
- 24.3. Market Revenue, by Type (2017-2030)
- 24.4. Market Revenue, by Drug Type (2017-2030)
- 24.5. Market Revenue, by Therapeutic Area (2017-2030)
- 24.6. Market Revenue, by End User (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Process (2017-2030)
- 25.3. Market Revenue, by Type (2017-2030)
- 25.4. Market Revenue, by Drug Type (2017-2030)
- 25.5. Market Revenue, by Therapeutic Area (2017-2030)
- 25.6. Market Revenue, by End User (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Process (2017-2030)
- 26.3. Market Revenue, by Type (2017-2030)
- 26.4. Market Revenue, by Drug Type (2017-2030)
- 26.5. Market Revenue, by Therapeutic Area (2017-2030)
- 26.6. Market Revenue, by End User (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Process (2017-2030)
- 27.3. Market Revenue, by Type (2017-2030)
- 27.4. Market Revenue, by Drug Type (2017-2030)
- 27.5. Market Revenue, by Therapeutic Area (2017-2030)
- 27.6. Market Revenue, by End User (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Process (2017-2030)
- 28.3. Market Revenue, by Type (2017-2030)
- 28.4. Market Revenue, by Drug Type (2017-2030)
- 28.5. Market Revenue, by Therapeutic Area (2017-2030)
- 28.6. Market Revenue, by End User (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Charles River Laboratories International Inc.
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. Eurofins Scientific Limited
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Frontage Laboratories Inc.
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. Galapagos NV
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. General Electric
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. Laboratory Corporation of America Holdings
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. Thermo Fisher Scientific Inc.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. Syngene International Limited
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
- 30.9. WuXi AppTec
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
